Menlo Park, CA (PRWEB) December 13, 2012
DNA2.0, the leading bioengineering solutions provider, today announced that it has been awarded US patent 8,323,930 for a new cloning method that facilitates high-throughput manufacturing of synthetic DNA. The company’s new technology for one-step DNA cloning is based on the DNA topoisomerase enzyme and its capacity to nick and reanneal DNA. Because the process does not rely on PCR, DNA2.0’s method ensures no introduced sequence errors in the cloned version of the newly manufactured synthetic gene.
“Industrializing the production of synthetic genes requires more than simply increasing the capacity and accuracy of oligonucleotide synthesis. Accordingly, DNA2.0 has developed a new method to efficiently and consistently clone assembled oligonucleotides to generate clonal entities in a one-step process,” said Jeremy Minshull, CEO and cofounder of DNA2.0. “DNA2.0 is proud to be an innovation leader so that our customers can focus on their research rather than reinventing the wheel. We are excited to add this patent to our growing portfolio of technological achievements in synthetic biology.”
DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis, and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit http://www.DNA20.com.